OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Recruiting · NCT06182696 · Registry updated 2024-05-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM | Relapsed and/or Refractory Multiple Myeloma | Recruiting | Phase 1 / Phase 2 | 2024-05-31 | NCT06182696 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| OriCell Therapeutics Co., Ltd. | 5 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Gobroad Hospital | Beijing | China | 10 |
| The First Affiliated Hospital College of Medicine Zhejiang University | Hangzhou | China | 1 |
| The First Affiliated Hospital with Nanjing Medical University | Nanjing | China | 4 |
| Tongji Hospital of Tongji University | Shanghai | China | 10 |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan | China | 8 |